Trade

with

Verastem Inc
(NASDAQ: VSTM)
AdChoices
9.59
+0.63
+7.03%
After Hours :
9.59
0.00
0.00%

Open

9.18

Previous Close

8.96

Volume (Avg)

401.69k (192.64k)

Day's Range

8.97-9.92

52Wk Range

7.10-16.60

Market Cap.

247.83M

Dividend Rate ( Yield )

-

Beta

0.59

Shares Outstanding

25.84M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -41.20M

    • Market Cap.

    • 247.83M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.59

    • Forward P/E

    • -4.21

    • Price/Sales

    • -

    • Price/Book Value

    • 2.50

    • Price/Cash flow

    • -7.14

      • EBITDA

      • -41.17M

      • Return on Capital %

      • -51.25

      • Return on Equity %

      • -55.21

      • Return on Assets %

      • -51.25

      • Book Value/Share

      • 3.84

      • Shares Outstanding

      • 25.84M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 23.75

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -2.12

        • Cashflow Estimate

        • -1.58

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.65

              • 2.92

              • Quick Ratio

              • 12.53

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.08

              • 2.21

              • Book Value/Share

              • 3.84

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.71

                • 217.39

                • P/E Ratio 5-Year High

                • -9.87

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.28

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 2.34

                • 8.61

                • Price/Cash Flow Ratio

                • -7.14

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -55.21

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -51.25

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -55.21

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -41.40M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -7.14
                      Ownership

                      Institutional Ownership

                      81.62%

                      Top 10 Institutions

                      52.83%

                      Mutual Fund Ownership

                      28.50%

                      Float

                      84.22%

                      5% / Insider Ownership

                      5.62%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,343,833

                      • 0.00

                      • 5.20

                      • JPM Global Healthcare

                      •  

                        890,197

                      • 0.00

                      • 3.44

                      • Tekla Healthcare Investors

                      •  

                        635,199

                      • 0.00

                      • 2.47

                      • Prudential Jennison Health Sciences

                      •  

                        444,512

                      • 0.00

                      • 1.72

                      • Putnam Global Health Care Fund

                      •  

                        355,447

                      • 0.00

                      • 1.38

                      • Vanguard Total Stock Mkt Idx

                      •  

                        345,500

                      • 0.00

                      • 1.34

                      • iShares Nasdaq Biotechnology

                      •  

                        334,305

                      • -0.47

                      • 1.36

                      • iShares Russell 2000 (AU)

                      •  

                        309,215

                      • -1.45

                      • 1.26

                      • Tekla Life Sciences Investors

                      •  

                        283,628

                      • 0.00

                      • 1.10

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        202,208

                      • 0.00

                      • 0.78

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        1,546,041

                      • -7.48%

                      • 6.01

                      • Bessemer Venture Partners

                      •  

                        1,190,358

                      • 0.00%

                      • 4.63

                      • Eastern Capital LTD

                      •  

                        1,142,857

                      • 0.00%

                      • 4.51

                      • Platinum Investment Management Ltd

                      •  

                        1,077,674

                      • +37.99%

                      • 4.19

                      • Tekla Capital Management LLC

                      •  

                        918,827

                      • 0.00%

                      • 3.57

                      • J P Morgan Asset Management (UK) Ltd

                      •  

                        890,197

                      • 0.00%

                      • 3.46

                      • BlackRock Fund Advisors

                      •  

                        821,988

                      • +3.41%

                      • 3.20

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      -

                      Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells...more. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential ther...moreapies for certain cancers, including mesothelioma, ovarian and lung. The Company’s solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company’s competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.lessless

                      Key People

                      Mr. Robert Forrester

                      CEO/Director/President

                      Christoph H. Westphal,M.D.,PhD

                      Chairman of the Board/Co-Founder/Director

                      John B. Green

                      CFO/Chief Accounting Officer

                      Dr. Jonathan Pachter, PhD

                      Vice President, Divisional

                      Monica Singh

                      General Counsel/Vice President/Secretary

                      • Verastem Inc

                      • 215 First Street

                      • Cambridge, MA 02142

                      • USA.Map

                      • Phone: +1 617 252-9300

                      • Fax: -

                      • verastem.com

                      Incorporated

                      2010

                      Employees

                      30

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: